China-based Ascletis Pharma Inc (HKEX code: 1672) has received approval from the National Medical Products Administration (NMPA) for its all-oral Hepatitis C virus (HCV) treatment, for marketing in China, it was reported on Thursday.
The all-oral HCV treatment is Ravidasvir (Asclevir) in combination with Danoprevir (Ganovo).
The company's phase II/III clinical trial has indicated that the treatment regimen showed a 99% cure rate with a short treatment duration of 12 weeks in genotype one patients, and in patients with baseline NS5A resistance mutations, the treatment Regimen indicated a cure rate of 100% (SVR12). National Science and Technology Major Project has chosen both Ravidasvir and Danoprevir for 'Innovative Drug Development' programs. Presidio Pharmaceuticals Inc, a clinical stage pharmaceutical company, licensed Ravidasvir.
argenx advances ARGX-119 to registrational study for congenital myasthenic syndromes
hVIVO supports Cidara Therapeutics' positive Phase 2b influenza study results
Sanofi's riliprubart receives orphan drug designation in Japan for CIDP
HUTCHMED gains China approval for ORPATHYS and TAGRISSO combination in lung cancer
Hikma Pharmaceuticals USA announces USD1bn of new US investment
UCB reports positive Phase 3 results for fenfluramine in CDKL5 deficiency disorder